Transparency is a good way for patients to learn about their doctors' relationships with drug companies, the Pew Prescription Project's Allan Coukell told the Washington Post, which looked Tuesday at physician-industry relationships from a consumer and ph

The White House, in its efforts to line up industry support for health reform, announced an agreement this spring with the Pharmaceutical Researchers and Manufacturers of America (PhRMA) to discount senior drug costs and save $80 billion over the next dec

Medical Device Safety Act would restore needed safeguards and allow victims to be compensated When 2 ½ year old Avery DeGroh’s defibrillator shocked her nine times because of a broken lead, her mother “grabbed her to hug her, and…could feel all the electr

This week, a federal court in Massachusetts granted final approval for a $350 million settlement to reimburse consumers and insurers who were victims of the alleged scheme to raise the prices of hundreds of prescription drugs by 5%.  The settlement stems

Industry should stop funding physician education. That message was delivered – again and again yesterday – to the Senate Special Committee on Aging. Under the chairmanship of Senator Herb Kohl (D-WI), lead co-sponsor of the Physician Payments Sunshine Act

An editorial in last week’s Washington Post recognized the significance of banning pay-for-delay settlements and the potential benefit to prescription drug consumers. As mentioned in the editorial, the current law’s intent to allow generic drugs to come

The Association of Clinical Researchers and Educators, a group convened to defend unregulated industry-physician relationships and fight a growing movement to limit the influence of marketing on medicine, held its charter meeting on the campus of Brigham

So where does lying to the Federal Trade Commission (FTC) get you? For the former vice president of Strategy and Medical and External Affairs of Bristol-Myers Squibb Company (BMS), Dr. Andrew G. Bodnar, it gets you a book deal, or at least a

On July 6, the Department of Justice (DOJ) filed a brief in the U.S. Court of Appeals for the 2nd Circuit expressing a new DOJ view on pay-for-delay settlements. The brief urges the 2nd Circuit to regard pay-for-delay settlements as “presumptively unlawf